BeOne Medicines (ONC) Operating Leases (2019 - 2026)

BeOne Medicines (ONC) has reported Operating Leases for 8 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 9.52% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (down 9.52% YoY), while the FY2025 annual figure was $52.9 million, up 19.57% from the prior year.
• Operating Leases slipped to $49.7 million in Q1 2026 per ONC's latest filing, from $52.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $54.9 million in Q1 2025 and bottomed at $17.7 million in Q1 2024.
• Historically, Operating Leases has averaged $39.7 million across 5 years, with a median of $40.0 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Leases slumped 46.87% — and 2025, when it jumped 209.76%.
• BeOne Medicines' Operating Leases stood at $34.5 million in 2022, then advanced by 28.06% to $44.2 million in 2023, then gained by 0.17% to $44.3 million in 2024, then gained by 19.57% to $52.9 million in 2025, then fell by 6.18% to $49.7 million in 2026.
• Business Quant data shows ONC's Operating Leases at $49.7 million in Q1 2026, $52.9 million in Q4 2025, and $51.4 million in Q3 2025.